Diagnosis and management of tumor lysis syndrome.

Tumor lysis syndrome (TLS) is an oncological emergency characterized by a classic tetrad of hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. Risk assessment and prophylactic therapy is critical in preventing this oncological emergency. Treatment of established TLS involves aggressiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Puri, Isha, Sharma, Deep, Gunturu, Krishna S., Ahmed, Andaleeb A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426989/
https://www.ncbi.nlm.nih.gov/pubmed/32850076
http://dx.doi.org/10.1080/20009666.2020.1761185
_version_ 1783570799469264896
author Puri, Isha
Sharma, Deep
Gunturu, Krishna S.
Ahmed, Andaleeb A.
author_facet Puri, Isha
Sharma, Deep
Gunturu, Krishna S.
Ahmed, Andaleeb A.
author_sort Puri, Isha
collection PubMed
description Tumor lysis syndrome (TLS) is an oncological emergency characterized by a classic tetrad of hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. Risk assessment and prophylactic therapy is critical in preventing this oncological emergency. Treatment of established TLS involves aggressive hydration, electrolyte management, and the use of hypouricemic agents.
format Online
Article
Text
id pubmed-7426989
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-74269892020-08-25 Diagnosis and management of tumor lysis syndrome. Puri, Isha Sharma, Deep Gunturu, Krishna S. Ahmed, Andaleeb A. J Community Hosp Intern Med Perspect Review Article Tumor lysis syndrome (TLS) is an oncological emergency characterized by a classic tetrad of hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. Risk assessment and prophylactic therapy is critical in preventing this oncological emergency. Treatment of established TLS involves aggressive hydration, electrolyte management, and the use of hypouricemic agents. Taylor & Francis 2020-06-14 /pmc/articles/PMC7426989/ /pubmed/32850076 http://dx.doi.org/10.1080/20009666.2020.1761185 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of Greater Baltimore Medical Center. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Puri, Isha
Sharma, Deep
Gunturu, Krishna S.
Ahmed, Andaleeb A.
Diagnosis and management of tumor lysis syndrome.
title Diagnosis and management of tumor lysis syndrome.
title_full Diagnosis and management of tumor lysis syndrome.
title_fullStr Diagnosis and management of tumor lysis syndrome.
title_full_unstemmed Diagnosis and management of tumor lysis syndrome.
title_short Diagnosis and management of tumor lysis syndrome.
title_sort diagnosis and management of tumor lysis syndrome.
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426989/
https://www.ncbi.nlm.nih.gov/pubmed/32850076
http://dx.doi.org/10.1080/20009666.2020.1761185
work_keys_str_mv AT puriisha diagnosisandmanagementoftumorlysissyndrome
AT sharmadeep diagnosisandmanagementoftumorlysissyndrome
AT gunturukrishnas diagnosisandmanagementoftumorlysissyndrome
AT ahmedandaleeba diagnosisandmanagementoftumorlysissyndrome

Ejemplares similares